Comparative Pharmacology
Head-to-head clinical analysis: APIDRA versus NOVOLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APIDRA versus NOVOLIN N.
APIDRA vs NOVOLIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glulisine is a rapid-acting insulin analog that lowers blood glucose by binding to and activating insulin receptors on cells, facilitating glucose uptake into muscle and adipose tissue, and inhibiting hepatic glucose production.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Subcutaneous injection 0.2-0.4 units/kg once daily or divided twice daily, or as part of basal-bolus regimen with 50-70% of total daily insulin as prandial insulin given within 15 minutes before or within 20 minutes after starting a meal.
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal elimination half-life is approximately 30 minutes. This short half-life allows for flexible dosing and rapid clearance, but necessitates multiple daily injections or continuous subcutaneous insulin infusion.
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Primarily renal; ~60% of a dose is excreted as metabolites and unchanged drug in urine. Fecal elimination is minimal (<10%).
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Category C
Category C
Insulin
Insulin